Hamid Nasri
1*, Mohammad Reza Ardalan
21 Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran
2 Chronic Kidney Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
*Corresponding Author: *Corresponding author: Prof. Hamid Nasri, Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran. , Email:
hamidnasri@med.mui.ac.ir
Abstract
Implication for health policy/practice/research/medical education:It is well known that hyperuricemia is an independent risk factor for renal progression in IgA nephropathy, however it is unclear the effect of allopurinol therapy, on the clinical outcome in hyperuricemic IgAN. It is possible that appropriate treatment by allopurinol be a reasonable modality in these patients. However, to better understand the kidney protective efficacy of allopurinol in IgAN patients, more clinical studies are suggested.